Roche Pharmaceutical Development and Sales Overview

Major pending approvals 2022 US EU Japan-Chugai Gazyva 1L CLL Filed March 2022 Phesgo HER-2+ BC/CC Filed Sept 2022 Lunsumio (mosunetuzumab) RG7828 3L+FL RG6321 Susvimo (PDS) WAMD China Polivy RG7596 Filed Dec 2021 Actemra Filed April 2021 1L DLBCL Filed Nov 2021 RG7159 Hemlibra Polivy RG1569 COVID-19 pneumonia RG6013 mild to moderate hemophilia A RG7596 Filed Jan 2022 Filed Oct 2021 r/r DLBCL Filed Dec 2021 RG6264 Cotellic RG7421 histiocytosis RG6396 Filed April 2022 RG7446 Tecentriq ASPS RG6152 Filed June 2022 Polivy RG7596 1L DLBCL (US) RG7916 Filed Aug 2022 RG6413+ RG6412 RG6026 RG1569 Gavreto RET+ MTC, TC Filed Nov 2021 Xofluza influenza pediatric Filed Nov 2021 Evrysdi SMA presymptomatic pediatric <2mo Filed Nov 2021 Ronapreve* SARS-CoV-2 hospitalized Filed Jan 2022 glofitamab 3L+ DLBCL Filed April 2022 Actemra SS-ILD Filed Aug 2022 RG6107 crovalimab PNH Filed Aug 2022 Status as of October 18, 2022 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other Roche PDS-Port Delivery System with ranibizumab *Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 57 57

View entire presentation